Medistep HealthcareShare price, financial results, shareholding and management

NSE Emerge · MEDISTEPHygiene and healthcare productsListed 18 Aug 2025IPO ₹43Catch them young
medistephc.com ↗Live price on NSE ↗ISIN INE0UOY01019 · Lot 3,000 shares · ₹56,700
₹18.90
+3.80% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹27 cr
Stock P/E
4.5peers 44.2
Book value
₹26.6
Price to book
0.71
EV / operating profit
3.8
Market cap to sales
0.38
Returns and growth
ROCE · FY26
27.0%
ROE · FY26
21.7%
ROE, 3-year average
25.1%
Operating margin · FY26
11.6%peers 15.4%
Sales growth, 3 years
+42.7%
Profit growth, 3 years
+44.4%
Safety
Debt to equity
0.14peers 0.26
Borrowings
₹5.2 cr
Interest cover
33.0×
Cash from business / op. profit
-236%
Debtor days
203
Pledged
0.00%
Ownership and share
Promoter holding
68.96%
Change in promoter holding
0.00 pts
Shareholders
514
52-week high / low
₹30 / ₹17
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Medistep Healthcare share price chart

₹18.90-35.71% 1 year

Close on 19 Nov 2026 · +3.85% on the day · Vol 21,000

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
-11.7%
3 months
+1.9%
6 months
-10.0%
1 year
-35.7%
Since IPO
-56.0%
Traded a day, 20 days
₹0.02 cr
Taken for delivery
91%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+43%+44%
3 years, a year--
Latest half, H2 FY26+26%+22%

About Medistep Healthcare: business, products and customers

Medistep Healthcare makes sanitary pads and an energy drink powder in Gujarat, and trades medicines, supplements, hygiene goods and surgical supplies to distributors and stockists. Its shares trade on NSE Emerge.

The company was formed in June 2023 and took over MG Pharma, a trading business owned by promoter Prajapati Hetalben Girdharilal, in July 2023. It started making DryStep sanitary pads and VitaStep-Z energy powder in January 2024 at a small unit in Bareja, Kheda, Gujarat. Alongside its own products it trades pharmaceutical formulations, nutraceuticals, intimate care products and surgical supplies such as syringes, needles and masks.

Most sales are traded goods, and almost all revenue goes through distributors and stockists rather than pharmacies or hospitals. Trading earns a thin margin, so the small manufacturing line carries most of the profit: in FY25 it made about a quarter of revenue but nearly four fifths of segment profit. Revenue and margin therefore move with how much of the mix is the company's own pads and powder.

Read more about the business

Distributors are given long credit, so profit has not turned into cash: trade receivables roughly doubled in FY26 and the company drew a bank cash credit line, while most of the IPO money was set aside for working capital. The offer document names Achyut Healthcare and Fabino Enterprises as listed companies in a similar line of healthcare products and trading.

From the offer document (business, capacity, customers, objects of the issue and peers), the FY26 annual report (directors' report, financial statements and notes) and the FY25 annual report (related party note).

Read the deeper study ↓

In its favour

  • Sales have grown fast: 43% a year last year.
  • It earns a high return on the money it uses: ROCE 27% in FY26.
  • It has little debt for its size: debt to equity 0.14.
  • The promoters own a large part of the company: 68.96%.

To watch

  • Collection of the ₹39.4 cr owed by customers at March 2026 (Annual report FY26, p.67).
  • Use of the IPO money for working capital and the new machinery for new products at Bareja (Offer document, p.91 and p.95).
  • Any loans, guarantees or investments made under the ₹100 cr limit put to shareholders in FY26 (Annual report FY26, p.17).
  • Progress towards the stated turnover goal of ₹250 cr by FY2030 (Offer document, p.146).
  • Customers take longer to pay than before: 203 days in FY26, against 159 in FY24.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Medistep Healthcare revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew roughly in step with sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
020406080Sales, FY24: 31.6 ₹ cr31.6Net profit, FY24: 2.9 ₹ cr2.9FY24Sales, FY25: 49.7 ₹ cr49.7Net profit, FY25: 4.1 ₹ cr4.1FY25Sales, FY26: 70.8 ₹ cr70.8Net profit, FY26: 6 ₹ cr6FY26
The latest halves, ₹ crore
SalesNet profit
010203040Sales, H1FY25: 21.3 ₹ cr21.3Net profit, H1FY25: 1.7 ₹ cr1.7H1FY25Sales, H2FY25: 28.4 ₹ cr28.4Net profit, H2FY25: 2.5 ₹ cr2.5H2FY25Sales, H1FY26: 35.1 ₹ cr35.1Net profit, H1FY26: 3 ₹ cr3H1FY26Sales, H2FY26: 35.8 ₹ cr35.8Net profit, H2FY26: 3 ₹ cr3H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before.

Medistep Healthcare half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY25H2FY25H1FY26H2FY26
Sales21.2528.4035.0735.76
Expenses18.9625.0931.0831.50
Operating profit2.293.313.994.26
OPM10.8%11.7%11.4%11.9%
Interest0.020.0100.25
Depreciation0.020.020.010.01
Profit before tax2.253.283.974.03
Net profit1.692.462.973.01

Medistep Healthcare profit and loss

Full years to March, FY24 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY24FY25FY26
Sales31.6049.6570.83
Expenses27.6444.0462.58
Operating profit3.965.618.25
OPM12.5%11.3%11.6%
Other income0.0100.02
Interest0.060.040.25
Depreciation0.020.030.03
Profit before tax3.895.548
Tax rate25.2%25.3%25.2%
Net profit2.914.145.98
EPS ₹5.943.964.68
Dividend payout0.0%0.0%0.0%

Medistep Healthcare profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%FY24: 12.5%12.5%FY24FY25: 11.3%11.3%FY25FY26: 11.6%11.6%FY26
Per cent
FY24FY25FY26
Operating margin12.5%11.3%11.6%
Tax rate25.2%25.3%25.2%
ROCE·37.2%27.0%
ROE·28.5%21.7%
Dividend payout0.0%0.0%0.0%

Medistep Healthcare debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. It borrowed much more last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
010203040Net worth, FY24: 11.7 ₹ cr11.7Borrowings, FY24: 0.3 ₹ cr0.3FY24Net worth, FY25: 17.4 ₹ cr17.4Borrowings, FY25: 0.6 ₹ cr0.6FY25Net worth, FY26: 37.8 ₹ cr37.8Borrowings, FY26: 5.2 ₹ cr5.2FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-20-10010Cash from the business, FY24: -7.1 ₹ cr-7.1Net profit, FY24: 2.9 ₹ cr2.9FY24Cash from the business, FY25: 0 ₹ cr0Net profit, FY25: 4.1 ₹ cr4.1FY25Cash from the business, FY26: -19.5 ₹ cr-19.5Net profit, FY26: 6 ₹ cr6FY26

Bars below the line are cash going out.

Medistep Healthcare balance sheet

At each 31 March · ₹ crore

₹ crore
FY24FY25FY26
Equity capital4.9010.4714.21
Reserves6.796.8923.62
Net worth11.6917.3637.82
Borrowings0.330.645.18
Other liabilities2.9357.30
Total liabilities14.952350.30
Fixed assets0.150.140.12
Capital work in progress000
Investments000
Other assets14.8022.8650.18
Receivables··39.39
Inventory··6.18
Cash··0.61
Trade payables··3.65

Medistep Healthcare cash flow

₹ crore

₹ crore
FY24FY25FY26
Cash from operations-7.110.02-19.48
Cash from investing-0.150-0.01
Cash from financing7.241.2818.79
Net cash flow-0.021.30-0.70
Capital spending··0.01

Working capital

Days

Days
FY24FY25FY26
Debtor days159148203
Inventory days12937
Days payable192122
Cash conversion cycle152137218
Working capital days134117191

Medistep Healthcare peers and competitors

Listed SME companies in the same industry

By sales, Medistep Healthcare is number 4 of the 8 listed SME companies in personal products.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Anondita Medicare1,90356.01373437.0%0.26
H. R. Hygiene Products13912.61301114.0%0.51
Recode Studios48644.2801121.0%0.30
Medistep Healthcare274.570.8611.6%0.14
Aakaar Medical Technologies10115.1676.615.4%0.34
Macobs Technologies19567.241.42.98.3%0.06
Ravelcare6813.1275.226.2%0.00
Novateor Research Laboratories23227.03.80.1-2.6%0.09
Median of the 7 others13944.2676.615.4%0.26

Medistep Healthcare shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.

Promoters
68.96%
0.00 pts since Aug 25
Indian institutions (DIIs)
0.00%
at Aug 25; not in the latest pattern
HNIs (over ₹2 lakh each)
10.56%
+5.87 pts since Aug 25
Small holders (up to ₹2 lakh)
16.98%
-5.61 pts since Aug 25
Companies and others
3.50%
-0.26 pts since Aug 25
Number of shareholders
514
525 in Aug 25

Medistep Healthcare shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Aug 25Sep 25Mar 26
Promoters68.96%68.96%68.96%
Indian institutions (DIIs)0.00%--
HNIs (over ₹2 lakh each)4.69%8.07%10.56%
Small holders (up to ₹2 lakh)22.59%18.54%16.98%
Companies and others3.76%4.43%3.50%
Number of shareholders525578514

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Medistep Healthcare study: the business from its own documents

Read from 3 of the company's own documents

Medistep Healthcare so far

From the company's own record

  1. June 2023Company formed
  2. 18 Aug 2025Listed on NSE Emerge at ₹43
  3. 31 March 2026Promoters at 68.96%
  4. 18 Aug 2025Highest close since listing, ₹50.35

Medistep Healthcare key facts from the filings

Each figure with the document it comes from

FY26 revenue
₹70.8 cr
Up from ₹49.7 cr in FY25.Annual report FY26, p.19
FY26 profit after tax
₹6.0 cr
Up from ₹4.1 cr in FY25.Annual report FY26, p.19
Owed by customers
₹39.4 cr
Trade receivables at March 2026, against ₹20.1 cr a year earlier.Annual report FY26, p.67
Own products
26.5%
Share of FY25 revenue from pads and powder the company makes; the rest is trading.Offer document, p.144 and p.145
Profit from manufacturing
₹4.8 cr
FY25 segment profit from manufacturing, against ₹1.3 cr from trading on far larger sales.Offer document, p.248
Show 5 more facts
Top ten customers
89.3%
Share of FY25 revenue, with no binding agreements in place.Offer document, p.36 and p.153
Through distributors
96%
Share of FY25 revenue sold to distributors and stockists. Reported results; our arithmetic.Offer document, p.145
Pad capacity used
60.6%
Use of the doubled pad line, 25.92 lakh packets per half year, from October 2024 to March 2025.Offer document, p.168
Bank borrowing
₹4.9 cr
State Bank of India cash credit at March 2026; there was almost no bank debt a year earlier.Annual report FY26, p.65
IPO money for working capital
₹12.3 cr
Of net proceeds of ₹14.5 cr from the issue at ₹43 a share; ₹0.5 cr was for new machinery.Offer document, p.91 and p.26

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The offer document sets a goal of ₹250 cr of turnover by the end of FY2030. The company says it will install new machinery for new products at Bareja from the IPO money and expects to run it at full capacity. In FY26 shareholders were asked to raise the limit on loans, guarantees and investments the board may make to ₹100 cr, which the company says is for its growth plans.

₹250 crTurnover goalBy end of FY2030, offer document
₹0.5 crNew machinery from IPO moneyFor new products at Bareja
₹100 crProposed loans and investments limitFY26 AGM notice

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

The company earns most of its profit from the pads and powder it makes, and adds a thin margin on a much larger trading business.

Its weak spot is cash: a few distributors take most of the goods on long credit, so profit has been tied up in money owed.

WatchCan it set its own prices?It makes everyday hygiene products and trades common medicines, where price is the main way to compete.
The evidence. The annual report names intense pricing pressure from domestic and multinational players as a risk.Annual report FY26, p.37
WatchHow strong is it against rivals?A small regional maker and trader with one compact unit and a thin team.
The evidence. One manufacturing unit of 371.61 sq m at Bareja; six permanent employees at March 2026; the company competes with large and mid size firms on quality, relationships and price.Offer document, p.155 and p.170; Annual report FY26, p.34
WatchWho are its customers?A few distributors and stockists take nearly everything, without contracts, and the list changes a lot from year to year.
The evidence. Top ten customers were 89.3% of FY25 revenue and 97.3% in FY23, with different names leading each year; sales to firms owned by its key people were ₹5.6 cr in FY25 and almost nil in FY26.Offer document, p.36, p.153; Annual report FY25, p.68; Annual report FY26, p.70
WatchDoes it need a lot of money?The plant costs little, but the credit given to distributors needs a lot of money.
The evidence. Receivables rose from ₹20.1 cr to ₹39.4 cr in FY26; ₹12.3 cr of the IPO went to working capital and a ₹4.9 cr bank cash credit was drawn.Annual report FY26, p.65 and p.67; Offer document, p.91
AverageCan it keep finding new work?The pad line has spare room and new machinery for new products is planned, but there is no order book.
The evidence. Pad capacity was doubled to 25.92 lakh packets per half year and was 60.6% used; energy powder capacity was under 4% used.Offer document, p.168 and p.95
AverageDo good and bad years swing a lot?Demand for hygiene products and medicines is steady, though the energy powder sells mainly in summer.
The evidence. Energy powder demand runs mainly from April to July; revenue has risen each year since the company was formed.Offer document, p.168; Annual report FY26, p.19

Who runs Medistep Healthcare?

Promoters, directors and officers; tap a name for the background

GLGirdhari Lal PrajapatPromoter, Founder and Managing Director · holds 9.94%

Bachelor of Pharmacy from Rajasthan University of Health Sciences, Jaipur, with over 12 years in the pharmaceutical industry. Started in the production department at Cadila Pharmaceuticals, then worked in sales and marketing and as a pharmacist at AIMS Hospital, Paldi, Ahmedabad. A director since incorporation and Managing Director from February 2024, paid ₹6 lakh a year.

Offer document, p.188, p.190 and p.193
PHPrajapati Hetalben GirdharilalPromoter and Non-Executive Director · holds 50.08%

Six years in pharmaceutical sales, stock and market operations; a sales executive at Nand Kishor Medical and General Store from 2014 to 2016, then owner of MG Pharma, the business the company took over. The offer document states Prajapati Hetalben Girdharilal is the wife of Girdhari Lal Prajapat.

Offer document, p.189, p.190 and p.192
DVDabhi Vipul GobarbhaiPromoter and Executive Director · holds 8.94%

Bachelor of Ayurvedic Medicine and Surgery from Gujarat Ayurved University, with over 19 years of hospital practice at Hope Neurocare, Rudraksh Institute of Medical Science and Narol ICU and Trauma Center, Ahmedabad. A director since incorporation; draws no pay.

Offer document, p.189, p.191 and p.193
JPJagdish PrajapatiPromoter and Chief Financial Officer · holds Nil

Bachelor of Commerce from Gujarat University and CA Intermediate, with six years in accounts, finance and taxation at Virtual Accounting Solutions LLP, Lalit K Sharma and Company and A and D Consulting. CFO since February 2024.

Offer document, p.26, p.199 and p.200
KAKhoda Anandbhai JitendrabhaiIndependent Director

Medical degree from Vikram University, Ujjain, with over 15 years in healthcare; partner of Astha Hospital, Bareja and a director of Rudra Super Speciality Hospital Private Limited.

Offer document, p.190 and p.191
DKDodiya Kapilbhai RaysinhbhaiIndependent Director

Medical degree from Hemchandracharya North Gujarat University, Patan, with eight years in hospitals; partner of Jeevandeep Hospital, Matar and Shree Krishna Multispeciality Hospital, Bareja.

Offer document, p.189 to p.191

Medistep Healthcare latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹35.8 cr (+26%), net profit ₹3 cr (+22%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 68.96%.

Medistep Healthcare annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Offer document
Annual reports

Medistep Healthcare share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Medistep Healthcare's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,42,09,546 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY24 to FY26.
  • iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.

Questions people ask about Medistep Healthcare

What does Medistep Healthcare do?

Medistep Healthcare makes sanitary pads and an energy drink powder in Gujarat, and trades medicines, supplements, hygiene goods and surgical supplies to distributors and stockists. Its shares trade on NSE Emerge.

What is the share price of Medistep Healthcare?

₹18.9 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Medistep Healthcare?

₹27 cr at the close on 19 Nov 2026, on 1,42,09,546 shares.

What is the P/E of Medistep Healthcare?

4.5 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Medistep Healthcare's revenue and profit?

Revenue ₹71 cr and profit after tax ₹6 cr in FY26.

Who are the promoters of Medistep Healthcare?

Girdhari Lal Prajapat, Prajapati Hetalben Girdharilal, Dabhi Vipul Gobarbhai, Jagdish Prajapati; promoters held 68.96% at 31 March 2026.

What was the IPO price of Medistep Healthcare?

₹43 a share; it listed on 18 Aug 2025.

What is Medistep Healthcare's website?

www.medistephc.com

More SME companies like Medistep Healthcare

Other listed SME companies in personal products, the closest in size first, each read from its own documents.

Every listed SME company in Personal Products → · SME companies listed in 2025 →

Built from 2 annual reports, 1 offer document, 14 exchange announcements, 3 shareholding patterns and 3 years of reported results. Every figure carries its source; where the documents are silent, the page says so.